Breast Cancer
Conditions
Keywords
breast cancer, estrogen receptor-negative breast cancer, estrogen receptor-positive breast cancer, progesterone receptor-negative breast cancer, progesterone receptor-positive breast cancer, triple-negative breast cancer, HER2-negative breast cancer, HER2-positive breast cancer
Brief summary
RATIONALE: Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer. PURPOSE: This research study is looking at tumor tissue samples from patients who have undergone surgery for breast cancer.
Detailed description
OBJECTIVES: * To determine if candidate genes display differential expression between normal and cancer breast tissues. OUTLINE: Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
Interventions
GENETICgene expression analysis
Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
OTHERimmunohistochemistry staining method
Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
OTHERlaboratory biomarker analysis
Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
Sponsors
Case Comprehensive Cancer Center
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Diagnosis of breast cancer * Tissue samples available * Samples are selected based on presence or absence of tumor receptors, (i.e.; estrogen, progesterone, and HER2 receptors) and grouped into following 4 categories: * Estrogen receptor (ER)-positive/progesterone receptor (PR)-positive/HER2-negative * ER-positive/PR-positive/ HER2-positive by FISH * ER-negative/PR-negative/HER2-positive * ER-negative/PR-negative/HER2-negative(triple negative or basal-type cancers) PATIENT CHARACTERISTICS: * Menopausal status not specified PRIOR CONCURRENT THERAPY: * Not specified
Exclusion criteria
* There are no
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Differential expression of candidate genes between normal and cancer breast tissues | non-applicable | Approximately 5 slides of each tumor will be collected to provide sufficient samples for replicate staining, if necessary, as well as a staining for a positive control |
Countries
United States
Outcome results
None listed